-
公开(公告)号:US20140056880A1
公开(公告)日:2014-02-27
申请号:US14012167
申请日:2013-08-28
申请人: Tinya Abrams , Paul Barsanti , Yu Ding , David Duhl , Wooseok Han , Cheng Hu , Yue Pan
发明人: Tinya Abrams , Paul Barsanti , Yu Ding , David Duhl , Wooseok Han , Cheng Hu , Yue Pan
IPC分类号: C07D403/12 , C07D413/14 , C07D207/10 , A61K31/5377 , A61K45/06 , C07D405/14 , A61K31/4196
CPC分类号: C07D403/12 , A61K31/4196 , A61K31/5377 , A61K45/06 , C07D207/10 , C07D249/08 , C07D405/12 , C07D405/14 , C07D413/14
摘要: The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.
摘要翻译: 本发明提供式I的三唑化合物:如本文进一步描述的。 本发明还提供了包含治疗有效量的式I化合物的药物组合物,以及治疗在哺乳动物患者中至少部分地由KSP介导的病症的方法,包括向需要这种治疗的哺乳动物患者施用 治疗有效量的式I化合物。
-
公开(公告)号:US20130012560A1
公开(公告)日:2013-01-10
申请号:US13546713
申请日:2012-07-11
申请人: Tinya Abrams , Paul Barsanti , David Duhl , Michel Faure , Paul A. Renhowe , Annette Olga Walter
发明人: Tinya Abrams , Paul Barsanti , David Duhl , Michel Faure , Paul A. Renhowe , Annette Olga Walter
IPC分类号: A61K31/4164 , A61P35/04 , A61P35/02 , A61P35/00
CPC分类号: A61K31/4164 , C07D233/61
摘要: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.
摘要翻译: 本发明提供了具有取代的咪唑环的新化合物,以及使用这些化合物治疗某些疾病如血液癌和实体瘤的方法。 本发明的化合物是抑制KSP的三取代的咪唑衍生物。 这些化合物也可用于治疗药物抗性肿瘤,例如表达升高的P-糖蛋白水平的实体瘤。
-
公开(公告)号:US20090239922A1
公开(公告)日:2009-09-24
申请号:US12313923
申请日:2008-11-25
申请人: Tinya Abrams , Paul Barsanti , David Duhl , Michel Faure , Paul A. Renhowe , Annette Olga Walter
发明人: Tinya Abrams , Paul Barsanti , David Duhl , Michel Faure , Paul A. Renhowe , Annette Olga Walter
IPC分类号: A61K31/4174 , C07D233/61 , A61P35/00
CPC分类号: A61K31/4164 , C07D233/61
摘要: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.
摘要翻译: 本发明提供了具有取代的咪唑环的新化合物,以及使用这些化合物治疗某些疾病如血液癌和实体瘤的方法。 本发明的化合物是抑制KSP的三取代的咪唑衍生物。 这些化合物也可用于治疗药物抗性肿瘤,例如表达升高的P-糖蛋白水平的实体瘤。
-
公开(公告)号:US20080200462A1
公开(公告)日:2008-08-21
申请号:US11937426
申请日:2007-11-08
申请人: Yi Xia , Kris Mendenhall , Paul A. Barsanti , Annette O. Walter , David Duhl , Paul A. Renhowe
发明人: Yi Xia , Kris Mendenhall , Paul A. Barsanti , Annette O. Walter , David Duhl , Paul A. Renhowe
IPC分类号: A61K31/5377 , C07D249/08 , A61K31/4196 , A61K31/4439 , A61P35/04 , C07D401/12 , C07D413/12
CPC分类号: C07D401/12 , C07D249/08 , C07D403/12 , C07D413/12
摘要: Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:
摘要翻译: 公开了式(I)的新的取代的吡唑和三唑化合物及其药学上可接受的盐,酯或前药,衍生物的组合物和药学上可接受的载体,及其用途:
-
公开(公告)号:US07902240B2
公开(公告)日:2011-03-08
申请号:US11937426
申请日:2007-11-08
申请人: Yi Xia , Kris Mendenhall , Paul A. Barsanti , Annette O. Walter , David Duhl , Paul A. Renhowe
发明人: Yi Xia , Kris Mendenhall , Paul A. Barsanti , Annette O. Walter , David Duhl , Paul A. Renhowe
IPC分类号: A61K31/41 , C07D249/08
CPC分类号: C07D401/12 , C07D249/08 , C07D403/12 , C07D413/12
摘要: Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:
摘要翻译: 公开了式(I)的新的取代的吡唑和三唑化合物及其药学上可接受的盐,酯或前药,衍生物的组合物和药学上可接受的载体,及其用途:
-
公开(公告)号:US08664256B2
公开(公告)日:2014-03-04
申请号:US13546713
申请日:2012-07-11
申请人: Tinya Abrams , Paul A. Barsanti , David Duhl , Michel Faure , Paul A. Renhowe , Annette Olga Walter
发明人: Tinya Abrams , Paul A. Barsanti , David Duhl , Michel Faure , Paul A. Renhowe , Annette Olga Walter
IPC分类号: A61K31/4164
CPC分类号: A61K31/4164 , C07D233/61
摘要: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.
摘要翻译: 本发明提供了具有取代的咪唑环的新化合物,以及使用这些化合物治疗某些疾病如血液癌和实体瘤的方法。 本发明的化合物是抑制KSP的三取代的咪唑衍生物。 这些化合物也可用于治疗药物抗性肿瘤,例如表达升高的P-糖蛋白水平的实体瘤。
-
公开(公告)号:US20050038027A1
公开(公告)日:2005-02-17
申请号:US10818187
申请日:2004-04-05
申请人: Rustum Boyce , David Duhl
发明人: Rustum Boyce , David Duhl
IPC分类号: C07D401/12 , A61K31/496 , A61K31/519 , A61K31/53 , A61P3/04 , A61P3/10 , A61P7/00 , A61P43/00 , C07D209/46 , C07D209/48 , C07D217/24 , C07D235/08 , C07D235/10 , C07D403/12 , C07D487/02 , C07D491/02 , A61K31/498 , A61K31/503 , C07D498/02
CPC分类号: C07D209/46 , C07D209/48 , C07D217/24 , C07D235/08 , C07D235/10
摘要: Compounds having the general structure III are provided: where D is N or C; W is selected from Z1, Z2, and Z3 are independently selected from CR8 and N; and the other variables have the values described herein. Compounds of formula III have useful properties for controlling diseases related to MC4-R action in humans including obesity and type II diabetes.
摘要翻译: 提供具有通式III的化合物:其中D是N或C; W选自Z 1,Z 2和Z 3独立地选自CR 8和N; 并且其他变量具有本文所述的值。 式III化合物具有用于控制与包括肥胖和II型糖尿病在内的人类MC4-R作用有关的疾病的有用性质。
-
公开(公告)号:US07189727B2
公开(公告)日:2007-03-13
申请号:US10818187
申请日:2004-04-05
申请人: Rustum Boyce , David Duhl
发明人: Rustum Boyce , David Duhl
IPC分类号: A61K31/495 , A61K31/5375 , C07D401/12 , C07D413/12
CPC分类号: C07D209/46 , C07D209/48 , C07D217/24 , C07D235/08 , C07D235/10
摘要: Compounds having the general structure III are provided: where D is N or C; W is selected from Z1, Z2, and Z3 are independently selected from CR8 and N; and the other variables have the values described herein. Compounds of formula III have useful properties for controlling diseases related to MC4-R action in humans including obesity and type II diabetes.
摘要翻译: 提供具有通式III的化合物:其中D为N或C; W选自Z 1,Z 2,Z 3,Z 3独立地选自CR 8和N; 并且其他变量具有本文所述的值。 式III化合物具有用于控制与包括肥胖和II型糖尿病在内的人类MC4-R作用有关的疾病的有用性质。
-
公开(公告)号:US06960582B2
公开(公告)日:2005-11-01
申请号:US10426937
申请日:2003-04-30
申请人: Rustum Boyce , David Duhl
发明人: Rustum Boyce , David Duhl
IPC分类号: C07D401/12 , A61K31/496 , A61K31/519 , A61K31/53 , A61P3/04 , A61P3/10 , A61P7/00 , A61P43/00 , C07D209/46 , C07D209/48 , C07D217/24 , C07D235/08 , C07D235/10 , C07D403/12 , C07D487/02 , A61K31/5375 , C07D413/12
CPC分类号: C07D209/46 , C07D209/48 , C07D217/24 , C07D235/08 , C07D235/10
摘要: Compounds having the general structure II are provided: A is selected from the group consisting of C or CH and X and Y are independently selected from the group consisting of CH2, N, C═O, C═S, (CR6R7)n, S═O, SO2, O, NR9, S, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n where n is 1, 2, or 3. W is selected from the group consisting of and Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. L is selected from the group consisting of N, O, S, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Compounds of formula II are agonists of the melanocortin-4 receptor (“MC4-R”) and therefore may have useful properties for controlling diseases related to MC4-R action in humans, such as obesity and type II diabetes.
摘要翻译: 提供具有通式II的化合物:A选自C或CH,X和Y独立地选自CH 2,N,CO,CS,(CR SO 2,SO 2,O,NR 9,SO 3,SO 2,SO 2, ,(C) - (CR) - (CR 6) - (CR 6) 其中n为1,2或3.W选自Z 1,...,S 2,...,N 2, Z 2,Z 3,Z 3,Z 3独立地选自取代的碳和氮。 L选自由N,O,S,SO,SO 2,C(O),NC(O),NC(S),OC(O),OC(S) ,C(NR 10),C(NOR 10)和共价键。 式II化合物是黑皮质素-4受体(“MC4-R”)的激动剂,因此可能具有控制人类MC4-R作用相关疾病如肥胖和II型糖尿病的有用性质。
-
公开(公告)号:US07456183B2
公开(公告)日:2008-11-25
申请号:US10474331
申请日:2002-04-08
申请人: Daniel Chu , Rustum Boyce , David Duhl , Bryan Chang
发明人: Daniel Chu , Rustum Boyce , David Duhl , Bryan Chang
IPC分类号: A61K31/47 , A61K31/425 , A61K31/415 , A61K31/40 , A61P7/00 , C07D209/02 , C07D209/44 , C07D209/46 , C07D209/48 , C07D217/22 , C07D235/24 , C07D235/28 , C07D277/62 , C07D403/02
CPC分类号: C07D209/46 , C07D209/48 , C07D217/24 , C07D235/08 , C07D235/10
摘要: Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH2, N, NR9, C═O, C═S, S═O, SO2, S, O, (CR6R7)n, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of (formula I) and L is selected from the group consisting of N, O, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r2) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.
摘要翻译: 提供具有一般结构I的化合物。 X和Y独立地选自CH 2,N,NR 9,CO,CS,SO,SO 2,S ,(O) - (CR 6),(O) - (CR 6) C(-S) - (CR 6 R 7)N O>,和C(-S) - (CR 6) 其中n为1,2或3.W选自(式I),L选自N,O,SO,SO 2, C(O),NC(O),NC(S),OC(O),OC(S),C(NR 10) ,和共价键。 Z 1,Z 2,Z 3和Z 3独立地选自取代的碳和氮。 式I化合物是黑皮质素-4受体(“MC-4r2”)的激动剂,因此可能具有控制人类MC-4r作用相关疾病如肥胖和II型糖尿病的有用性质。
-
-
-
-
-
-
-
-
-